Early breast cancer that is ER-positive and HER2-negative Early breast cancer that is ER-positive and HER2-negative
Conditions
Interventions
None listed
Sponsors
Koizumi Kei
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients aged 18 years or older. 2.Patients who underwent Oncotype DX Breast Recurrence Score testing through the Oncotype DX Breast Recurrence Score Testing Program and had their recurrence score measured. 3.Patients with ER-positive, HER2-negative early-stage breast cancer who had no lymph node metastasis or 1-3 positive lymph nodes.
Exclusion criteria
Exclusion criteria: 1. Patients who underwent Oncotype DX Breast Recurrence Score testing through the Oncotype DX Breast Recurrence Score Program but whose recurrence scores were not measured or were unknown. 2. Patients who did not give their consent or withdrew their consent from the study. 3. Patients with bilateral breast cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Invasive disease free survival: iDFS | — |
Secondary
| Measure | Time frame |
|---|---|
| -Overall survival (OS) -Disease-free survival (DFS) -Distant disease-free survival (DDFS) -Distribution of recurrence scores based on clinical pathological factors in the entire group that underwent Oncotype DX and treatment selection -Treatment selection status and prognosis, including the proportion of chemotherapy administration by recurrence score -Correlation between Oncotype DX recurrence score and OS, DFS, and DDFS with S-1 administration -Correlation between Oncotype DX recurrence score and iDFS, OS, DFS, and DDFS with abemaciclib administration -Treatment completion rate and reasons for discontinuation | — |
Contacts
Public ContactKei Koizumi
Hamamatsu University Hospital
Outcome results
None listed